FDA Advisory Panel review of Guardant Health Shield Blood Test on May 23

Guardant Health announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration Medical Devices Advisory Committee is scheduled to review the premarket approval PMA application for the company’s Shield(TM) blood test for colorectal cancer CRC screening on Thursday, May 23. “We look forward to discussing with the FDA Advisory Committee and its panel of experts the clinical data from our ECLIPSE study and the potential for the Shield blood test to overcome the barriers of current screening methods and offer a new, more convenient screening option that will detect colorectal cancer in the early stages, when it is most treatable,” said AmirAli Talasaz, co-CEO of Guardant Health.